Global Consortium, Inc., is adding a Medical Grade Nutraceutical's Division
- The division will be comprised of doctors from different specialties
- White label products are being designed to market to doctors
- The first tested products are expected to hit the market by June
Coconut Creek, FL -- March 14, 2019 -- InvestorsHub NewsWire -- Global Consortium, Inc., (OTCPINK: GCGX) is expanding Infused Edibles with a new Nutraceuticals line.
The new line will consist of lotions, balms, ointments, liquids, pills, and powders.
The new division will be overseen by medical doctors and veterinarians of varying specialties, custom designing infused formulas not currently available. These proprietary formulas will be designed as a holistic approach to help treat a wide range of ailments in humans and animals.
Each new formula will be compounded and tested by a lab in California prior to being made available to the general public.
Some of the formulas will made available directly to the public, while others will be marketed to medical practices as "White Labeled" products that can be custom tailored to each doctors practice.
The first two specialty products are expected to be ready to hit the market by the end of June.
Global has seen a steady interest in its "Cannabis Mall Tour" and will be updating the website with the final terms and conditions shortly. If you have an interest, you can pre-register at http://www.gcgx.org/tour/
There is a scheduled investor conference call for 4:30 PM eastern standard time on Friday, March 22, 2019.
Global Consortium CEO Matt Dwyer and other members of the GCGX management team will provide updates on recent developments and discuss the goals for the Company in 2019.
In addition, interested parties have the opportunity to submit questions concerning the Company prior to the call to Stuart Smith at SmallCapVoice.Com, Inc. via email: firstname.lastname@example.org by 12:00 PM eastern standard time on Monday March 18th, 2019. Mr. Smith will compile a list of questions and submit them to the Company prior to the conference call. Which questions will be addressed will be based on the relevance to the shareholder base, and the question's appropriateness in light of public disclosure rules.
To access the call:
Dial-In Number: 1-857-232-0157
Access Code: 422095
For those unable to participate in the conference call at that time, a replay will be available at https://www.smallcapvoice.com/gcgx/ shortly after the call has concluded.
Global Consortium, Inc., is building America's First Cannabis Mall, which when completed will house Manufacturing, Distribution, Delivery, Retail, Testing, and Cultivation all under one 64,000 square foot building. The Mall will house the largest Manufacturing facility of THC and CBD Distillate and Edibles believed to be operational in the United States.
Global Consortium, Inc., in compliance with SEC regulations, may in the future use social media outlets like Facebook or Twitter and its own website to announce key information in compliance with Reg. FD.
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, estimates of services and equipment markets, the release of corporate apps, growth of the platform, target markets, product releases, product demand and, business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also consider that any investment in securities is at risk.
Details of the Company's business, finances, appointments, and agreements can be found as part of the Company's continuous public disclosure on otcmarkets.com.
For additional information about this release please contact: